Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 5/20 | 0.51 |
| ▸ | CA2 | P00918 | 5/20 | 0.51 |
| ▸ | CA4 | P22748 | 5/20 | 0.51 |
| ▸ | CA6 | P23280 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6907617 | 1.00 | CA1 (0.51) | CA1CA2CA4CA6KMT2A | |
| SCHEMBL5873450 | 1.00 | CA1 (0.51) | CA1CA2CA4CA6KMT2A | |
| SCHEMBL15048937 | 0.98 | — | — | |
| SCHEMBL13766051 | 0.98 | — | — | |
| SCHEMBL1117680 | 0.98 | — | — | |
| SCHEMBL16151463 | 0.91 | — | — | |
| SCHEMBL28815447 | 0.91 | — | — | |
| SCHEMBL7199479 | 0.91 | — | — | |
| Ethylene Glycol SCHEMBL28420640 | 0.88 | NPC1 (0.41) | CA1CA2CA4CA6KMT2A | |
| SCHEMBL3819009 | 0.83 | KDM4E (0.50) | CA1CA2CA4CA6KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9371265-B2 | Compositions and methods related to inhibitors of JAK kinase | EP PHARMA INC (US) | 2016-06-21 | — | — | US | disclosed |
| US-9371265-B2 | Compositions and methods related to inhibitors of JAK kinase | EP PHARMA INC (US) | 2016-06-21 | — | — | US | disclosed |
| US-9371265-B2 | Compositions and methods related to inhibitors of JAK kinase | EP PHARMA INC (US) | 2016-06-21 | — | — | US | disclosed |
| US-20150087621-A1 | COMPOSITIONS AND METHODS RELATED TO INHIBITORS OF JAK KINASE | EP PHARMA INC (US) | 2015-03-26 | — | — | US | disclosed |
| US-20150087621-A1 | COMPOSITIONS AND METHODS RELATED TO INHIBITORS OF JAK KINASE | EP PHARMA INC (US) | 2015-03-26 | — | — | US | disclosed |
| US-20150087621-A1 | COMPOSITIONS AND METHODS RELATED TO INHIBITORS OF JAK KINASE | EP PHARMA INC (US) | 2015-03-26 | — | — | US | disclosed |
| WO-2013148638-A2 | COMPOSITIONS AND METHODS RELATED TO INHIBITORS OF JAK KINASE | EP PHARMA, INC. (US) | 2013-10-03 | — | — | WO | disclosed |
| US-20040091515-A1 | Noxious-insect repellent | KANEBO, LTD. | 2004-05-13 | — | — | US | disclosed |
| US-6686396-B2 | NO OFFENSIVE ODOR AND EXHIBIT EXCELLENT NOXIOUS-INSECT REPELLING EFFECT AND DURABILITY | KANEBO, LTD. (JP) | 2004-02-03 | — | — | US | disclosed |
| US-6677384-B1 | CARBOCYCLIC ALCOHOLS SUCH AS 2-HYDROXYMETHYL-3,3,5-TRIMETHYL-CYCLOHEXANOL USED AS ODORLESS, DURABLE LOTIONS TO PREVENT DISEASES | KANEBO, LTD. (JP) | 2004-01-13 | — | — | US | disclosed |
| US-20020143070-A1 | Noxious-insect repellent | KANEBO, LTD. | 2002-10-03 | — | — | US | disclosed |
| US-6372804-B1 | HYDROXYALKYLCYCLOALKANOLS REPELLENTS | KANEBO, LTD. (JP) | 2002-04-16 | — | — | US | disclosed |
| US-6130255-A | EXPOSING NOXIOUS INSECTS TO REPELLENT COMPRISING 2-(1-HYDROXYALKYL)-CYCLOALKANOLS HAVING NO OFFENSIVE ODOR | KAO CORPORATION (JP) | 2000-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150087621-A1 | COMPOSITIONS AND METHODS RELATED TO INHIBITORS OF JAK KINASE | JAK1, JAK2, JAK3 | CA1 1692/4885CA2 2760/4885CA4 3799/4885 |
| US-20020143070-A1 | Noxious-insect repellent | OPRM1, OPRD1, L3MBTL1 | CA1 4038/4885CA2 3608/4885CA4 4745/4885 |
| US-20040091515-A1 | Noxious-insect repellent | OPRM1, OPRD1, OPRK1 | CA1 4042/4885CA2 3942/4885CA4 4742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.